Agile_Logo-color on white.jpg
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
June 15, 2023 16:05 ET | Agile Therapeutics, Inc.
FPA Women’s Health is the largest independent family planning service network in the United States, and the Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now the exclusive patch...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
June 13, 2023 16:05 ET | Agile Therapeutics, Inc.
Agile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™ Partnership Expected to Augment Future Growth in the Retail...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
May 25, 2023 16:05 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
May 22, 2023 20:00 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its...
Agile_Logo-color on white.jpg
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
May 11, 2023 16:05 ET | Agile Therapeutics, Inc.
Twirla Delivers Single-Quarter Records for Retail and Non-Retail Demand; Both Channels Up 20% in First Quarter 2023 vs Fourth Quarter 2022 Total OPEX down 8% in First Quarter 2023 vs Fourth...
Agile_Logo-color on white.jpg
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
May 08, 2023 08:00 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
April 28, 2023 08:01 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla®...
Agile_Logo-color on white.jpg
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
April 26, 2023 09:01 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it has received a notification letter from the Listing...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
April 10, 2023 16:30 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that its board of directors approved a 1-for-50...
Agile_Logo-color on white.jpg
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
March 22, 2023 16:05 ET | Agile Therapeutics, Inc.
Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged Twirla Demand and Factory Sales...